While Zika virus (ZIKV) infection induces mild disease in the majority of cases, it has 20 been identified as responsible for microcephaly and severe neurological disorders in recent 21 2015-2016 outbreaks in South America and the Caribbean. Since then, several prophylactic 22 vaccine strategies have been studied. Here, we describe the development of a ZIKV 23 candidate vaccine consisting of bivalent enveloped virus-like particles (eVLPs) expressing a 24 modified form of E and truncated NS1 (EG/NS1) proteins. In EG/NS1, the E 25 transmembrane/cytoplasmic tail has been replaced with those domains from the VSV G 26 protein and a -domain of NS1 was fused in-frame to Gag from Moloney murine leukemia 27 virus (MLV). Immunization of BALB/C mice demonstrated that bivalent EG/NS1 and 28 monovalent EG eVLPs induced comparable levels of antibody (Ab) titers but that EG/NS1 29 induced much higher neutralizing activity, comparable to naturally acquired anti-ZIKV 30 immunity. In contrast, monovalent NS1 eVLPs did not induce a significant anti-NS1 Ab 31 response but promoted strong T cell immunity that was also elicited with EG/NS1 eVLPs. 32 ZIKV challenge studies in C57BL/6-IFNR -/mice demonstrated that EG/NS1 eVLPs 33 conferred 100% protection against clinical disease after ZIKV challenge compared to 80% 34 protection after EG eVLP vaccination, with protection against challenge correlating with 35 neutralizing antibody titers and overt signs of infection. 36 37 Author Summary 38 Zika virus has caused rapidly spreading epidemics with potentially severe 39 neurological symptoms including microcephaly in new born babies. Rapid progress has been 40 made with several candidate vaccines under clinical evaluation but no vaccine or treatment is 41 yet available. In this context, we have produced and tested recombinant virus-like particles 42 that incorporate one or two Zika virus proteins, E and NS1 that have been modified for 43 optimal efficacy. Our immunogenicity studies in mice showed a synergistic effect of both 44 proteins in the bivalent vaccine. NS1 induced a strong T cell response enhancing the 45 neutralizing antibody production induced by the E protein. In challenge experiments, the 46 bivalent vaccine protected 100% of mice from clinical signs of Zika virus infection. These 47 products could be further used to explore Zika virus correlates of protection and evaluated as 48 vaccine candidates. 49 50
Introduction

51
Zika virus was first isolated in 1947 in a Rhesus sentinel monkey in Uganda, and was 52 not initially regarded as a significant human pathogen. However, large outbreaks in the 53 Pacific area including Yap Island in 2007; French Polynesia in 2013 to 2014) and the intense 54 epidemic in The Caribbean and South America in 2016 (1, 2) , led the WHO to declare ZIKV a 55 global public health emergency and the development of a vaccine a priority. Despite the end 56 of the outbreak and the ongoing decline of the number of cases, the need for a licensed ZIKV 57 vaccine remains critical for global public health. Indeed, the ZIKV infection is generally 58 asymptomatic or induces a mild fever, but is also associated to severe neurological 59 syndromes such as Guillain Barré Syndromes in adults, and microcephaly in infants. CDC 60 recently established that about one of seven children born to mother with ZIKV infection 61 during pregnancy had Zika-associated birth defect, a neurodevelopmental abnormality 62 possibly associated with congenital Zika virus infection, or both (3). In contrast to other 63 described arbovirus infections, ZIKV RNA can persist in human semen for a year or more, 64 and cases of sexual transmission have been reported (4). Cultured human germ cells are 65 permissive to ZIKV infection and can produce infectious virus (5). These latter features of 66 ZIKV could have impacts on demographics (6). There are still no licensed vaccines or 67 therapeutic measures against ZIKV infection. 68
More than forty ZIKV vaccine candidates have advanced through efficacy studies in 69 mice and non-human primates (NHP), nine progressed in Phase I clinical trials and among 70 them two entered Phase II. Early findings like current efforts suggested that the presence of 71 high titers of neutralizing antibodies against the ZIKV envelope protein E correlate with 72 protection (7-9). In addition, more recent studies have exposed an important role of CD4 + T-73 cell activation to develop and maintain an efficient protective response during ZIKA infection 74 (10,11). In accordance with these findings, a T-cell biased adenovirus vector expressing 75 prME has been shown to protect mice against ZIKV challenge without detectable levels of 76 ZIKV specific Ab. Finally, ZIKV vaccine candidates based on expression of the non-structural 77 protein NS1 have also shown protection of mice from ZIKV infection by inducing both 78 and cytoplasmic domains of the VSV-G protein (EG) (Fig 1) . Pelleted supernatants from all 110 conditions contained particles similar in size and morphology with typical MLV Gag particles 111 as shown by ns-TEM analysis (Fig 2A) and both prME and EG plasmids induced expression 112 of ZIKV E ( Fig 2B) . Preparations of EG-eVLPs contained a lower density of particles as 113 observed in nsTEM (Fig 2A) but contained higher expression of the E protein than in prME 114 eVLPs as indicated by Western blot analysis using anti-flavivirus mAb 4G2 ( Fig 2B) . 115
When injected into BALB/C mice, EG eVLPs induced anti-ZIKV E IgG titers that were 116 100 to 1000 times greater than eVLPs expressing wild-type full length prME ( Fig 3A) and in 7 117 of 8 mice, this strong IgG response was associated with a modest but significant neutralizing 118 activity ( Fig 3B) . Based on this data, and reproducible yields of eVLPs with elevated levels of 119 E protein contents, we selected EG as our preferred ZIKV E construct. 120 121
Production and characterization of bivalent EG/NS1 eVLPs 122
In an attempt to potentiate the antibody neutralizing response to ZIKV via enhanced 123 T cell help, we sought to develop bivalent eVLPs expressing NS1 protein as well as EG. As 124 NS1 is readily secreted by infected cells, it was fused in-frame with Gag to ensure its 125 retention inside the particles. The first set of experiment demonstrated that the full length 126 NS1 fused to the full length Gag (Gag-NS1) resulted in very poor yields of eVLP particles, as 127 indicated by very low levels of Gag protein detected by ELISA ( Fig 4A) . It is possible that the 128 elongated size of the Gag-NS1 fusion protein, together with the specific properties of NS1, 129 disrupted the architecture of the particles. This observation was consistent with our 130 unpublished previous studies showing that eVLPs stability was more difficult to achieve when 131
Gag was fused with an additional protein. A truncated form of NS1 corresponding to the 132 hydrophobic β-ladder domain was chosen because its homologous domain in  NS1 contains 133 multiple CD8 + and CD4 + T cell epitopes (26, 27) . Transfection with Gag-Truncated NS1 (Gag-134
Tr.NS1) DNA plasmid produced particles with expected yields ( Fig 4A) . Co-transfection with 135
Gag-Tr.NS1 and EG plasmids produced bivalent EG/NS1 eVLPs that expressed both and 136 EG and Gag-fused NS1 protein as shown by western blot analysis ( Fig 4B) . Optimization of the amounts of plasmid DNA enabled to obtain similar amounts of Gag and particle numbers 138 in bivalent and monovalent eVLPs for fair comparison of both preparations ( Fig 4A) . A 139 standard procedure using 0.4 µg/mL of either Gag or Gag-Tr.NS1 plasmid was used for 140 further studies. 141
Monovalent EG and prME eVLPs had a different appearance on CryoEM images 142 from bivalent EG/NS1 eVLPs ( Fig 4C) . Monovalent EG and prME eVLPs were multi-lamellar 143 particles with smooth surfaces, comparable to the appearance of typical MLV Gag particles 144 (28), with a smooth surface, like mature Zika virions (14). In contrast, bivalent EG/NS1 145 particles were predominantly uni-lamellar with a homogenous dense textured core and their 146 outer surface contained structures with dark densities protruding ~8-10 nm from the lipid 147 bilayers, and resembling spikes ( Fig 4C) . A similar impact on the core structure when using a 148 plasmid in which MLV Gag was fused with the CMV pp65 protein has been observed 149 (unpublished data). It is possible that the addition of a protein in frame with the Gag 150 sequence induced an alteration of the architecture of the MLV-Gag VLP core structure (28), 151 which may have prompted a conformation change in the surface EG protein due to altered 152 interactions between the Gag/NS1 core and the cytoplasmic tail of the EG protein (29). 
EG and EG/NS1 eVLPs protect mice from ZIKV challenge 173
The protective efficacy of the ZIKV eVLPs was examined in IFNR deficient mice fully 174 bred to a C57BL/6 background (C57BL/6-IFNR -/mice). These mice, like BALB/C mice are 175 able to mount protective immunity to ZIKV, but unlike the latter during primary infection, they 176 also display significant weight loss associated with other overt sign of infection such as hind 177 leg paralysis, the absence of which provides a facile read out of vaccine efficacy (30). Two 178 separated challenge experiments were conducted successively using identical protocols with 179 different groups. 180
A first challenge experiment was conducted to establish whether EG and EG/NS1 181 eVLPs could induce protective Ab immune response against ZIKV infection in the C57BL/6-182 IFNR -/mouse model. Four groups of 10 mice were injected with either saline, eVLPs 183 control expressing no ZIKV protein (Gag eVLP), EG eVLPs or EG/NS1 eVLPs. After a single 184 injection of EG or EG/NS1 eVLPs, the levels of anti-E IgG rapidly increased in the serum of 185 immunized mice peaking at 14 days after the second injection while the third injection 186 maintained Ab titers at a plateau ( Fig 7A) . 187
Evaluation of individual sera demonstrated that antibody responses were induced in 8 188 of 10 mice immunized with EG eVLPs and in 10 of 10 mice immunized with EG/NS1 eVLPs 189 in Exp.1 ( Fig 7B) . Neutralization activity against ZIKV was evaluated by PRNT90% 27 days 190 after the third injection. The sera from mice immunized with EG and EG/NS1 eVLPs possessed significant neutralizing activity which correlated with induction of antibody 192 responses in the mice (Figs 7B-C). Of interest, the sera from both mice with undetected 193 levels of anti-E had no neutralizing activity. A similar pattern of antibody response with higher 194 levels of IgG was observed in a second experiment were a group of mice were injected with 195 NS1 eVLPs instead of saline. In this experiment, all mice EG and EG/NS1 groups develop an 196
Ab response. We further analyzed the immunoglobin isotype usage in the sera from mice 197 from Exp.1. The IgG1 to IgG2b ratio indicated a predominant Th2 response in the EG group 198 as expected from Alum adjuvant. However a significant difference was observed with 199 bivalent EG/NS1 eVLPs, which promoted a switch towards IgG2b, that is usually associated 200 with cell-mediated immunity (Fig 8) . 201
After ZIKV challenge, mice were monitored daily for body weight change and 202 behavior. C57BL/6-IFNR -/mice in groups that received saline, Gag or NS1 eVLPs lost 203 body weight and developed hind leg paresis between days 8-10 after ZIKV injection (Fig 9) . 204
In marked contrast, in both experiments, mice immunized with either monovalent EG or 205 bivalent EG/NS1 ZIKV eVLPs showed only transient weight loss up to day 5 ( Fig.9A-B ), at 206 which point they began to regain normal body weight (achieved at day 10). Although both 207 monovalent EG eVLPs and bivalent EG/NS1 eVLPs groups showed statistically comparable 208 levels of protection and total IgG, 2/10 mice in the EG eVLPs group in exp.1 and 1/10 in 209 exp.2 ( Fig 9C) , developed hind leg paresis while none of the mice in the EG/NS1 group in 210 both experiments developed paresis at any time. Of interest, no significant anti-ZIKV IgG Ab 211 titer nor neutralizing activity was detected in neither of both non-protected mice from exp.1. 212
The second challenge experiment was aimed at determining if NS1 eVLPs used 213 alone could induce protection despite the absence of an efficient Ab response. Careful 214 observation of animal behavior showed that despite no significant protection from paralysis 215 compared to the control group ( Fig 9C) , some mice injected with NS1 eVLPs had milder 216 symptoms after day 10 ( Fig 9D) . In contrast, previous studies have demonstrated that vaccine candidates expressing full 248 length NS1 promoted efficient specific anti-NS1 neutralizing Ab responses associated with 249 protection against ZIKV infection (12,40-42). The discrepancy between our data and others 250 is likely due to alteration of NS1 presentation in two ways: i) the NS1 domain was fused with 251
Gag which can alter the tri-dimensional structure of NS1, ii) the NS1 domain is kept inside 252 the particles, reducing its accessibility to B cells. These data reveal another potential utility of 253 eVLPs for the analysis of T-cell versus B-cell responses against proteins, depending on their 254 location on or within the particles. Of note, the β-ladder of the NS1 is flexible and can interact 255 with many proteins. It is then possible that the use of a fusion protein Gag-NS1 can induce 256 alteration of the structure of the particle, and subsequent alteration of the coexpressed EG 257 protein, as suggested by the spike-like appearance of particles analyzed by cryo-EM (29). 258
As observed in BALB/C mice, EG and EG/NS1 eVLPs induced similar levels of anti-E 259
IgG in C57BL/6-IFNR -/mouse sera. However, in C57BL/6-IFNR -/mice, expression of EG 260 alone was sufficient to induce a strong neutralization antibody response equivalent to the one 261 observed in response to EG/NS1 eVLPs in 18 out of 20 mice across 2 independent studies. 262
Future studies may clarify if this difference is due to the genetic differences between 263 C57/BL6 and BALB/6, or to the IFNR pathway deficiency in C57/BL6-IFNR -/-. All mice that 264 mounted a nAb response, either in response to EG eVLPs or EG/NS1 eVLPs were protected 265 against experimental ZIKV infection. 266
These data confirm that neutralizing Ab responses are critical in protection against 267 ZIKV clinical disease and that the bivalent EG/NS1 eVLPs provide a more robust induction of 268 nAb response than monovalent EG eVLPs. In C57BL/6-IFNR -/mice, NS1 promoted a 269 switch towards a Th1 antibody response, emphasizing a strong effect on T-cell help even in 270 the presence of the Th2-adjuvant Alum. 271
It has been shown that an Adenovector ZIKV vaccine that induced a T-cell response 272
against the ZIKV envelop without any Ab response could protect C57BL/6 mice against ZIKV 273 infection (43). In our model, the C57BL/6-IFNR -/mice that received NS1 eVLP alone were 274 not protected from ZIKV infection in absence of an efficient nAb response. Further studies 275 would be necessary to determine the role of T cells in these IFNR deficient mice. 276
Flaviviruses possess a high degree of homology that leads to the abundant 277 production of cross-reactive Abs. While the mechanism for ADE has not been fully 278 elucidated, it is generally recognized that the presence of cross-reactive Abs with low 279 neutralizing potency are involved in ADE (15). The neutralization potency depends on the 280 affinity of the Abs and on the accessibility of the epitopes on the virions (44, 45) . In the 281 present study, mice immunized developed a high neutralizing response that correlated with 282 protection. Most potent nAb with low/no ADE have been described to be directed against 283 EDIII domain and quaternary epitopes from the DI/DII domain (46,47). Further structural 284 studies would determine whether the EG conformation at the surface of the eVLPs, would 285 present such epitopes in an optimal conformation for Ab production. When glycoproteins are expressed/present on the surface of eVLPs, one terminus of 295 the protein is anchored within the lipid bilayer, which imposes structural constraints not 296 readily observed with monomeric recombinant antigens. Moreover, by altering the 297 transmembrane domain/cytoplasmic tail of the glycoprotein, and/or the core particle structure 298 with which the cytoplasmic tail may interact, we have found that a novel presentation of 299 glycoproteins can be obtained that is associated with enrichment for antibodies with 300 neutralizing rather than just binding activity. This was demonstrated previously with eVLP 301 expression of a modified form of the CMV gB (25), similar to what we have observed with the 302 EG/NS1 ZIKV vaccine candidate presented in this study. The high degree of neutralization 303 obtained with EG/NS1 eVLPs may minimize the risk of ADE and is an attractive candidate for 304 further development as a prophylactic vaccine against ZIKV. 
Construction of plasmids 316
We used the ZIKV E sequence from Suriname isolate 2015 (23) (Genbank 317 KU312312) to construct a plasmid expressing the full length unmodified ZIKV prME and a 318 plasmid expressing the ectodomain of E fused with the transmembrane and cytoplasmic 319 domain of the VSV G protein (EG) (24). The ZIKV E sequences were preceded by a portion 320 of the sequence corresponding to the last 32 aa from the Zika virus capsid, as signal peptide. 321
For the production of VLP, we used a minimal cDNA sequence encoding a Gag polyprotein 322 of murine leukemia virus (MLV) (Gag without its C-terminal Pol sequence) or Gag-NS1 or 323
Gag-TR.NS1, were Gag was fused with full length NS1 or truncated NS1 consisting of the β-324 ladder domain of NS1 (aa 180 to 353). The design of the plasmids is summarized in Fig1. All final sequences were synthetized and optimized for mammalian cell expression at Genscript 326 (NJ), prior to subcloning into our in-house phCMV-expression plasmid (24). 327
All DNA plasmids were amplified in high-efficiency competent Escherichia coli cells 328 and purified with an endotoxin-free preparation kit using standard methodologies. Alum Adjuvant (Adju-Phos®, Brenntag) or saline control at monthly intervals or as indicated 381 for each experiment. Blood samples were collected every 2 weeks starting 2 weeks before 382 the first injection. Sera were either pooled or analyzed individually. 383
Challenge with 10,000 PFU of ZIKV Philippine 2013 was done 4 weeks after final 384 injection in C57BL/6-IFNR -/mice by the IP route. After infection, the mice were monitored 385 daily for body weight and clinical behavior as indicated in figure legends and blood was 386 collected at the end of the study. 387 388
Monitoring of immune response 389
Direct ELISA described earlier (25) was used to measure Ab binding titers to 390 recombinant E and NS1 protein from ZIKV (both from Meridian LifeScience). Plaque 391
Reduction Neutralization Test (PRNT) was used to measure ZIKV-specific neutralizing 392 activity in mouse sera. Vero cells were seeded at 3x10 5 cells/mL in 24-well plates 24h prior 393 PRNT. On the day of assay, virus and serially diluted serum samples were mixed and 394 incubated for 1h at 37±1°C. Supernatant from cell-seeded 24-well plates was decanted then 395 100 ml of virus/serum mixture was transferred from the dilution plate to the cells. After 1h 396 adsorption, agarose-containing overlay media was added and plates were incubated at 37°C, 397 5%CO2 for 3 days. The cells were fixed and stained using crystal violet solution and plaques 398 were counted visually. The neutralizing antibody titer was expressed as the highest test 399 serum dilution for which the virus infectivity is reduced by 50% or by 90%, as indicated in 400 legends. NS1-specific IFN and IL-5 production by ZIKV-specific splenic T cells were 401 enumerated by Enzyme Linked ImmunoSpot (ELISPOT) assay following manufacturer's 402 instructions (Mouse IFN-/IL-5 ELISpot Basic kits; Mabtech). Mouse splenocytes were left 403 unstimulated or stimulated with an NS1 peptide pool (PepMix ZIKV NS1 Ultra; JPT Peptide 404 Technologies, Germany) designed to cover the high sequence diversity of ZIKV. Spots were 405 
